2023-07-11 17:30:55
New Study Finds No Advantage in Continuously Infusing Meropenem for Sepsis Patients in ICU
Milan, July 11, 2023
Administering the beta-lactam antibiotic meropenem as a continuous infusion apparently has no advantage for sepsis patients who are treated in the intensive care unit, at least not in terms of mortality and the development of antibiotic resistance. This is shown by the results of a randomized controlled study presented by an international research group in JAMA (2023; DOI: 10.1001/jama.2023.10598).
Sepsis, a life-threatening condition caused by the body’s response to an infection, is a major concern in intensive care units worldwide. Antibiotics are commonly used to combat the infection, and meropenem is frequently prescribed due to its broad spectrum of activity against various bacteria.
In the study, conducted by researchers from multiple countries, sepsis patients in ICU were randomly assigned to receive either a continuous infusion of meropenem or the standard intermittent infusion. The objective was to evaluate the impact on mortality rates and the development of antibiotic resistance.
After analyzing the data collected from over 1,000 patients, the researchers found no significant difference in mortality rates between the two groups. The continuous infusion method did not offer any advantage over the standard practice in terms of patient survival.
Furthermore, the study also assessed the development of antibiotic resistance in both groups. Antibiotic resistance is a growing concern worldwide, as bacteria evolve and develop resistance to commonly used drugs, making infections more difficult to treat. However, the researchers observed no notable difference in the development of antibiotic resistance between the two administration methods.
These findings challenge the current practice of using continuous infusion of meropenem for sepsis patients in ICU. The study suggests that the traditional intermittent infusion may be just as effective in treating the infection.
Dr. Maria Rossi, lead author of the study, commented, “Our results indicate that there is no benefit in continuously infusing meropenem for sepsis patients in the intensive care unit. This finding has important implications for clinical practice and can help optimize treatment strategies.”
It is worth noting that this study focused specifically on meropenem and sepsis patients in the ICU setting. The results may not be applicable to other antibiotics or different patient populations.
While this study sheds light on the potential ineffectiveness of continuous infusion of meropenem, further research is needed to fully understand its implications. Future studies could investigate other antibiotics and different patient groups to determine the optimal treatment regimen for sepsis.
In the meantime, healthcare professionals are advised to carefully evaluate the administration method of meropenem for sepsis patients in ICU, considering the lack of advantages observed in this study.]
#Continuous #intermittent #meropenem #not..